Business Wire

SPEECH-PROCESSING

4.2.2020 11:03:11 CET | Business Wire | Press release

Share
Philips Introduces Subscription-based Speech-to-Text Software Portfolio

Speech Processing Solutions , the market leader in professional dictation, has announced that its portfolio of speech-to-text software is now available on a subscription basis. Flexible low monthly subscription costs make it easier for organizations to take advantage of the full range of available speech-to-text services.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200204005443/en/

Philips dictation and transcription software streamlines the document creation process and facilitates communication between authors and transcriptionists. It enables everything from automated file routing to an on-demand “pay as you go” transcription service or automatic speech recognition to help business of all sizes fulfill their unique needs.

“Philips speech-to-text software helps businesses reach their goals by helping them become even more efficient, profitable and successful, whether this means scoring new top clients or simply having more time for their current customers,” explains Dr. Thomas Brauner, CEO of Speech Processing Solutions.

High-tech innovation to boost voice-based productivity

Philips software is designed around the customers’ needs and has been developed in close collaboration with end-users. Philips understands that different businesses have personalized needs and preferences. Regardless of whether they are small, mid-sized or large, prefer an on-premise or cloud solution, or run an environment with a few laptops or a complex multi-branch setup across several countries, various voice-to-text options are available to help organizations address every business requirement.

The subscription-based speech-to-text portfolio includes Philips SpeechExec Pro, Philips SpeechExec Enterprise and SpeechLive. The new Philips SpeechExec Pro version 11.5 features a refreshed, more user-friendly interface and supports the latest operating systems available in the market. SpeechLive, Philips’s web dictation and transcription solution, now boasts a brand-new speech-to-text service that offers users speech recognition in real-time. This not only saves users time while working on documents, but also money and hassle as no additional speech recognition software needs to be purchased and installed. SpeechLive offers constant file access to increase mobility, helping professionals to work from anywhere and at any time. Now available as a one- or two-year subscription package, Philips SpeechExec Enterprise, which is ideal for large, multi-branch businesses, supports workflow processes that require central administration and virtual environments.

“Quick and effective communication is key in today’s complex business world. Working in a fast-paced environment requires effortless collaboration and efficient processes no matter what the size of your organization. Our Philips workflow software solutions allow you to do just that, while new subscription models enable businesses to be more agile and cost-efficient than ever before,” explains Dr. Brauner.

All Philips software is optimized to support the industry-leading range of Philips dictation devices including the SpeechMike series, the hands-free dictation headset SpeechOne and the Android-based SpeechAir.

For a free trial of Philips workflow solutions, go to: www.philips.com/speech

About Speech Processing Solutions

Speech Processing Solutions (SPS) is an international technology company and a global leader in dictation solutions. More than four million users worldwide work with speech-to-text solutions developed by SPS and sold under the Philips brand. These solutions include web-based and desktop workflow software as well as dictation devices. These smart solutions save users’ time and allow them to focus on their core tasks, making their business more efficient, customer-centric and profitable.

Headquartered in Vienna, Austria, SPS has regional offices in the United States, Canada, Australia, the United Kingdom, Germany, France, Belgium and Austria, as well as a network of more than 1000 distribution and implementation partners worldwide.

Link:

ClickThru

Social Media:

http://www.facebook.com/philipsdictation

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Andersen Consulting tilføjer House of Code for at styrke teknologi- og dataløsninger26.6.2026 20:01:00 CEST | Pressemeddelelse

Andersen Consulting forstærker sine kompetencer inden for teknologisk transformation gennem en samarbejdsaftale med House of Code, en global virksomhed med hovedkvarter i USA, der specialiserer sig i datadrevne platforme, automatisering og agentbaserede ai-løsninger. House of Code blev stiftet i 2001 og udvikler softwareløsninger samt yder rådgivning til energihandels- og finanssektoren med kunder, der spænder over hedgefonde, kapitalfonde og forsyningsvirksomheder. Virksomheden besidder dyb ekspertise inden for energihandel og risikostyring og hjælper organisationer med systemimplementering, forretningstransformation, dataautomatisering og ai-underbygget modernisering af arbejdsgange. Deres proprietære platform, Enterprise Platform for Integrated Compliance (EPIC), skaber en mere effektiv datastyring, automatiserer rapporteringsprocesser, forbedrer den driftsmæssige gennemsigtighed på tværs af virksomhedssystemer og skaber et fundament for opbygning af intelligente, agentbaserede arbe

Capco Recognized by OpenAI for Innovation and Responsible AI Leadership26.6.2026 20:00:00 CEST | Press release

Receives AI Governance & Risk Excellence Award at OpenAI Partner SummitCapco’s UK AI Lab wins OpenAI Codex Hackathon Global management and technology consultancy Capco, a Wipro company,has been recognized by OpenAI for both AI innovation and responsible AI leadership. Capco received the AI Governance & Risk Excellence Award at the recent OpenAI Partner Summit 2026 in San Francisco, highlighting Capco’s ability to deliver enterprise-grade AI outcomes in highly regulated environments. The award recognizes Capco’s expert advantage when helping financial services and energy organizations to scale AI with confidence, balancing innovation with strong governance to reduce risk, strengthen compliance and improve customer outcomes. This award follows Capco winning the OpenAI Codex Hackathon, where its UK AI Lab competed against more than 30 teams and over 100 participants from across the OpenAI partner ecosystem. Capco's winning entry Sentra – a consulting-led, AI-powered retail banking solutio

Incyte Announces Positive CHMP Opinion for Opzelura® (ruxolitinib) Cream for the Treatment of Adults with Moderate Atopic Dermatitis26.6.2026 13:30:00 CEST | Press release

If approved, Opzelura® (ruxolitinib) cream will be the first steroid-free, topical JAK treatment option in the European Union (EU) for adults with moderate atopic dermatitis (AD) for whom standard topical therapies have failedAD, the most common type of eczema which affects 230 million people globally,1 is a chronic, recurring, inflammatory and highly pruritic (itchy) skin condition that can have a significant impact on daily life2Phase 3 TRuE‑AD4 data supporting the positive CHMP opinion demonstrated that ruxolitinib cream met both co‑primary endpoints at Week 8, maintained disease control with as-needed treatment through Week 24 and was well tolerated3,4,5 Incyte (Nasdaq: INCY) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion recommending the approval of Opzelura® (ruxolitinib) cream for the treatment of moderate atopic dermatitis (AD) in adult patients for whom topical corticosteroids

Datroway® Recommended for Approval in the EU by CHMP as First-Line Treatment for Patients with Metastatic Triple Negative Breast Cancer Who Are Not Candidates for Immunotherapy26.6.2026 13:00:00 CEST | Press release

Recommendation based on TROPION-Breast02 phase 3 trial where Daiichi Sankyo and AstraZeneca’s Datroway showed a statistically significant and clinically meaningful improvement for the dual primary endpoints of overall survival and progression-free survival If approved, Datroway has potential to be the first TROP2 directed antibody drug conjugate for patients in EU with a demonstrated overall survival benefit as first-line treatment Datroway® (datopotamab deruxtecan) has been recommended for approval in the European Union (EU) as monotherapy for the first-line treatment of adult patients with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. Datroway is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use

DAYBU®(trofinetide) Recommended for Approval in the European Union by CHMP26.6.2026 12:49:00 CEST | Press release

-- European Commission decision expected in the coming months-- If approved, DAYBU®would become the first treatment for neurobehavioral symptoms of Rett syndrome in the European Union Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion following a re-examination procedure, recommending the granting of a marketing authorization for DAYBU® (trofinetide) for the treatment of neurobehavioral symptoms of Rett syndrome in adults and pediatric patients aged five years and older. If granted marketing authorization by the European Commission, DAYBU® would be the first therapy approved for this indication in the European Union (EU). “The CHMP’s positive opinion for DAYBU® is an important milestone in our mission to bring this innovative therapy to the EU, where there are no therapies specifically approved for the neurobehavioral symptoms of this devastating

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye